# Roivant Sciences Ltd. (ROIV) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Roivant Sciences Ltd.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2026 MD&A](/company/ROIV/mda/fy2026/): filed 2026-05-20; accession 0001635088-26-000061 (https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm); latest 10-K
- [FY 2025 MD&A](/company/ROIV/mda/fy2025/): filed 2025-05-29; accession 0001140361-25-020715 (https://www.sec.gov/Archives/edgar/data/1635088/000114036125020715/ef20047582_10k.htm)
- [FY 2024 MD&A](/company/ROIV/mda/fy2024/): filed 2024-05-30; accession 0001140361-24-028145 (https://www.sec.gov/Archives/edgar/data/1635088/000114036124028145/ef20026301_10k.htm)
- [FY 2023 MD&A](/company/ROIV/mda/fy2023/): filed 2023-06-28; accession 0001140361-23-031798 (https://www.sec.gov/Archives/edgar/data/1635088/000114036123031798/brhc20054745_10k.htm)
- [FY 2022 MD&A](/company/ROIV/mda/fy2022/): filed 2022-06-28; accession 0001193125-22-183362 (https://www.sec.gov/Archives/edgar/data/1635088/000119312522183362/d307489d10k.htm)

Back to /company/ROIV/